Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Brain Neoplasms 4Neuroblastoma 3Recurrence 2Melanoma 2Medulloblastoma 2Glioblastoma 2Neoplasm Metastasis 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Recurrence × TPI-287 × Clear all
NCT00867568 2024-08-06

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Milton S. Hershey Medical Center

Phase 1 Completed
18 enrolled 12 charts
CNS

Medulloblastoma, Neuroblastoma, Recurrence

NCT01340729 2013-04-05

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡